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Glycan1 microarrays: new angles and new strategies
Boglarka Donczo,*a Janos Kerekgyarto,b Zoltan Szurmaib and Andras Guttmana2
Carbohydrate microarrays, comprising hundreds to thousands of diﬀerent glycan structures on solid
surfaces in a spatially discrete pattern, are sensitive and versatile tools for the analysis of glycosylation
changes in complex biological samples. Glycoarrays are also suitable for monitoring multiple molecular
interactions with biomolecules where sugars are involved, oﬀering a large variety of bioassay options. In
this paper we review the most important glycan microarray types currently used with their main
applications, and discuss some of the future challenges the technology faces.
1 Introduction
The surface of virtually every living cell is decorated with highly
diverse glycan structures (glycoproteins, proteoglycans, glycos-
aminoglycans, etc.) that mediate a plethora of biological events.1
The emerging eld of glycobiology is devoted to dening the
structure–function relationship of glycans in numerous clini-
cally signicant biological processes, including, viral and
bacterial infection, tumorigenesis, the immune response and
many receptor-mediated signaling processes.2 Specic glyco-
sylation patterns may serve as markers for the early stages of
diseases or malignancy prior to metastasis.3 Glycan microarrays
represent a versatile toolset and provide the analytical means
for a large variety of such biomedical applications.
Glycoarray development started at the turn of the 21st
century, due to the critical need for global and high-throughput
methods for the systematic deciphering of glycosylation
patterns and identication of the specicities of glycan binding
proteins in order to enable detailed investigations of their bio-
logical signicance as well as their roles in various diseases.4
Aer a few years, following the rst reports on the use of glycan
microarrays, there was an outburst of interest in the generation
of glycan libraries, the development of eﬃcient glycan immo-
bilization methods on array surfaces, and their application in
the analysis of glycan binding proteins and other biomole-
cules.5 For the time being, glycan microarray applications are
mainly focused on the analysis of microorganism and
mammalian glycans.6 Since the comprehensive characterization
of complex glycan structures is a very demanding task, it has
taken many years for the eld to develop the appropriate
methods for glycoarray technology.7 Currently, one can utilize
the benets of that work by having access to structurally
dened, chemo/enzymatically synthesized glycans, which can
be used in an array format to shed light on functional recog-
nition and other important biochemical features that involve
glycosylation changes. The use of natural glycan arrays is
another strategy, which employs intact glycans derived from
natural sources.8,9
Microarray and microchip technologies have been success-
fully applied in genomics for decades. Protein and glycan
microarrays, on the other hand, share a common handicap as
the required capture molecules are not readily available and
their production, especially of glycan targets, is time consuming
and labor intensive. Finally, the amplication techniques
commonly used in nucleic acid analysis cannot be used in
proteomics and glycomics, therefore in most instances one
must work with limited amounts of samples, requiring detec-
tion methods with higher sensitivity and capture molecules
with greater specicity.10 This review gives a quick overview of
the glycoarray methods currently used and the latest develop-
ments in glycan microarray technology along with its major
analytical applications.
2 Brief overview of glycan microarray
fabrication methods
2.1 Contact and non-contact printing
Progress in microarray technology has provided the necessary
instrumentation in the form of arraying robots and printers that
can also be used to produce glycan microarrays.9 Scanning
devices, necessary for monitoring detection signals from
binding assays, are readily accessible as well. Glycan microarray
printing can generally be categorized into contact printing and
non-contact printing methods. In contact printing, a set of steel
pins (up to 48) are immersed into functionalized glycan solu-
tions in a multi-well source plate, and transferred by directly
touching the surface of the wafer slides. The amount of solution
delivered to the wafer is a function of the time the pin is in
contact with the surface. Depending on the pin type, the
samples are usually pre-blotted on a test surface to assure
consistent spot morphology before the actual microarray is
printed. The amount of pre-blotting and contact time can be
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tuned so that 0.5 nL per spot is printed rapidly and
reproducibly.11
Non-contact printing, in most instances is accomplished by
means of a piezoelectric printer that controls the delivery of the
reagent solution at a level of 0.3 nL (with <5% intra-tip vari-
ation) via a glass capillary using highly controlled electrical
impulses.12 This process can be ne-tuned by optimizing the
printing buﬀer composition for uniform delivery from each tip
(<10% inter-tip variation) to assure more precise printing,
relative to contact printing. The size and morphology of the
printed spots are relatively homogeneous even without con-
tacting the substrate, resulting in more precise readouts than
those obtained with contact printing.
The accuracy of printing by either approach is especially
important when quantitative or semi-quantitative studies are
required.13 Large arrays with thousands of spots or even
multiple sub-arrays on a single slide can be obtained by means
of non-contact printing, this permits multiple analyses to be
carried out on various sections of the slide.
2.2 Covalent and non-covalent binding
In recent years a large number of glycan based microarray
platforms, based on specic (covalent or non-covalent) immo-
bilization of chemically conjugated glycans on modied
surfaces, have been developed for high-throughput glycomic
studies.14 The actual problem in hand is to immobilize the
spotted glycan probes on the slides to produce stable micro-
arrays. Nitrocellulose coated glass slides are the most common
solid surface wafers for non-covalent attachment.15 Covalent
immobilization, on the other hand, provides more specic
attachment of the glycan probes through known functional
groups and orientation.16 For example, Park et al.17 have
synthesized maleimide-derivatized carbohydrates and have
spotted them onto a thiol-modied glass surface as shown in
Fig. 1. Ratner et al.8 utilized the opposite approach by reacting
thiol-derivatized carbohydrates with maleimide modied
surfaces. The Diels–Alder reaction was applied by Houseman
and Mrksich18 between cyclopentadiene-derivatized carbohy-
drates and a benzoquinone-functionalized surface. Recently,
Mercey et al.19 immobilized pyrrole-derivatized oligosaccharides
on modied surfaces by electro-copolymerization. Other func-
tionalized carbohydrates, such as those derivatized with amine-,
aldehyde-, hydrazide-, azide-groups have also been used to
construct carbohydrate microarrays.20
Most arrays are produced by printing monovalent carbohy-
drates onto a wafer surface. One of the strategies for modulating
probe density is to vary the concentration of the monovalent
carbohydrates in the print solution.22 With this approach,
however, the array surface acts as a multivalent scaﬀold. An
alternative strategy is rst to produce multivalent glycans with
varying density, and then to print the conjugates onto a solid
surface to generate an array with diﬀerent multivalent
components.23
In recent years, glycan microarrays have evolved towards
more advanced formats. Sugar structures have been directly
synthesized on bead surfaces, immobilized on silica wafers or
in ELISA plate wells.24 The advent of high precision robotic
arraying systems and high resolution imaging has also trans-
formed the eld by permitting substantial miniaturization, i.e.,
tens of thousands of carbohydrates or other array features can
be aﬃxed and imaged on a standard size microscope slide.
These microarrays permit high-throughput analysis of many
potential combinations of structures, while using only minis-
cule amounts of each of the carbohydrates as probes.25
2.3 Chemo/enzymatic synthesis
Glycan microarrays have been very successful in screening
glycan binding proteins to provide valuable information on
their specicity and binding properties. Most arrays are based
on glycan probes obtained by chemical synthesis and/or enzy-
matic methods. Thus, the expansion of such microarrays is
limited due to the inherent complexity of glycan structures and
diﬃculties in their synthesis. Natural glycan arrays are good
alternatives to further functional glycomics research.26
In the early days, libraries of glycans isolated from natural
sources were used to produce glycan microarray, and this class
of carbohydrates continues to be featured as components of
diverse glycan libraries. The synthesis of glycans by chemical or
chemo/enzymatic methods presents a viable alternative for the
isolation of natural glycans. But unfortunately, there are still no
systematic methods for the routine synthesis of glycans of
dened sequence like those available for DNA and proteins.1
Bohorov et al.27 developed a glycan derivatization method
using a modied hydroxylamine that retained a closed-ring
form at the reducing end. However, the lack of spectroscopic
properties of the linker limited its application in natural glycan
array development. Microscale derivatization, characterization,
and purication were essential due to the limited amounts of
glycans available. This strategy preserved the structural glycan
features required for antibody recognition, and allowed the
development of natural arrays of uorescent glycans in which
the cyclic pyranose structure of the reducing-end sugar residue
was retained.27,28 Although microscale derivatization of indi-
vidual free glycans oﬀered a rapid route for building a library,
the ability to derivatize a glycan mixture from natural sources
and to separate them was more attractive.29
A novel method has been reported for the generation of
quantiable glycan libraries by combining the protease
Fig. 1 Fabrication of glycan microarrays by respective immobilization
of maleimide or hydrazide-conjugated glycans onto thiol or epoxide
derivatized glass slides and their applications in (a) the determination of
the binding aﬃnities between glycans and proteins and (b) proﬁling of
glycosyltransferase activities. Reproduced with permission from
Ref. 21.5


























digestion of glycoproteins and Fmoc chemistry.4 Glycans were
derived by enzymatic or chemical cleavage from natural sour-
ces, such as glycoproteins and glycolipids, followed by reacting
them with a uorescent linker, and purication by multidi-
mensional chromatography to obtain tagged glycan libraries
(TGLs).30 The puried tagged glycans were printed as glycan
microarrays. Fig. 2 shows the use of such an oligosaccharide
microarray system.31,32
3 Glycoarray applications
Functional glycomics has attracted great interest due to
discoveries about the important roles of complex glyco-
conjugates in biological and pathological processes.33 Glycan
microarrays, in which glycans are immobilized onto activated
wafer surfaces and then treated with the sample of interest (e.g.,
cell lysates, proteins, pathogens, etc.), have been shown to be
successful in functional glycomics studies.266 Gene and protein
microarray technologies have transformed the investigation of
protein–glycan interactions into microscale based assays
capable of simultaneously analyzing hundreds to thousands of
glycans for their binding ability. This method can be used to test
the binding specicities of potential glycan binding proteins.
Detection of the interaction is usually accomplished by uo-
rescent methods, using lectins, antibodies, viruses and recep-
tors.34 In addition, microarray technology enables large
numbers of samples to be analyzed and can be used in various
biosensing assays with appropriate imaging methods, e.g.,
surface plasmon resonance.35 Glycoarrays hold the promise for
an individualized and vastly improved standard for healthcare,
which will have great impact on the way clinical diagnostics will
be practiced in the future. Printed glycan arrays (PGA) are one of
the newest of such high-throughput microarray technologies,
allowing the automated detection of an unlimited number of
natural and/or synthesized glycans in one experimental setting.
They are highly sensitive and signicantly reduce reagent
consumption.36,37
3.1 Glycan binding proteins
The generation of glycan microarrays with high specicities
toward glycan-binding proteins is important both for investi-
gating their biological functions and for analytical applications
in biomedical and diagnostic elds. Lectins specically recog-
nize carbohydrate motifs38 and Table 1 shows the primary sugar
specicities of some important lectins. Please note that most
lectins have additional structural requirements for binding.
Taylor and Drickamer39 reported that mannose binding
protein (a C-type lectin) did not bind to a glycan array even
though the array contained putative ligands and the protein was
active in other assays. Based on that, they suggested that the
array did not achieve suﬃcient density to support multivalent
Fig. 2 Fabrication diagram of a neoglycolipid based oligosaccharide array platform. Reproduced with permission from Ref. 32.


























binding. In another instance, binding of a plant lectin, con-
conavalin A, showed equivalent binding to high and low aﬃnity
mannose containing ligands when printed in high density, but
bound only to the high aﬃnity glycan printed at reduced
density.40 Such examples document the need for more system-
atic investigations into glycan presentation in diﬀerent array
formats.
Proteoglycans, glycoshingolipids and glycoproteins are the
major classes of mammalian glycans. There are numerous
mammalian glycan binding proteins (GBPs) outside of these
three major families, and new GBPs are continuously being
discovered. Notable results from the analysis of glycan arrays
include: M-colin, a soluble serum protein which is involved in
innate immunity was shown to bind sialylated glycans;40 and
malectin, an ER protein whose function was unknown until the
demonstration of its binding to a Glc3Man9GlcNAc2-N-linked
glycan, suggesting that it is involved in the processing of N-
linked glycan intermediates in the biosynthetic pathway.41
Numerous plant lectins have been identied and have been
demonstrated to have highly diverse specicities for glycan
ligands. They are widely recognized as being important tools in
glycobiology research,42,43 and lectins with novel specicities
continue to be identied and characterized. Glycan microarrays
have now become principle tools for dening the detailed
specicities of plant lectins.44
3.2 The mannose receptor
The mannose receptor (MR) is one of the best described
members of the type I transmembrane C-type lectins. MR has
been considered to be a potential entry receptor for a variety of
pathogens, and a target for regulation by human pathogen-
associated proteins suggesting relevance for this receptor in
the context of some human diseases. It also assists in the
clearance of pathogens, the capture of foreign antigens for
presentation to MHC-II compartments, the clearance of glyco-
protein hormones and extracellular peroxidases, endocytosis of
lysosomal acid phosphatase, as well as in the regulation of
glycoprotein homeostasis.45,46
Glycan microarray applications have been successfully used
in the analysis of cells for mannose receptor (MR) expression.
One of the surface receptors of MR recognizes extracellular host
and foreign substances with exposed terminal mannose resi-
dues. Through this binding, the MR mediates the internaliza-
tion of a wide range of pathogens and host-derived molecules,
inuences inammation; and mediates clearance of apoptotic
cells, endogenous hydrolases, and peroxidases.46 Under-
standing themolecular and cell biology of this receptor could be
key to develop strategies to contain infection and control
inammation.
3.3 Infectious diseases
Glycoarrays are being used more and more to extensively study
infectious diseases. Viruses and bacteria utilize the surface
carbohydrates of human cells as initial recognition and
attachment sites.47,48 The hemagglutinins on the surface of
inuenza viruses mediate attachment to the host cell by
binding sialylated carbohydrates and diﬀerent inuenza vari-
ants vary in their sialic acid binding prole.49 A good example of
the use of glycan microarrays to identify inuenza virus
subtypes from infected serum samples is to analyze their sugar
binding specicities.50 Fast glycoarray tests might detect inu-
enza strains in the early stages of an epidemic infection and
identify changes in the carbohydrate binding proles of
dangerous virus mutations.41 Another use of glycoarray tests is
a panel of Salmonella-related carbohydrate antigens employed
to analyze human sera from salmonellosis and healthy
patients.51
Glycosylphosphatidylinositol (GPI) glycolipids are present in
the plasmamembrane of Plasmodium falciparum, a parasite that
causes malaria in humans. GPI is an important toxin and
humans in malaria endemic regions oen produce high levels
of anti-GPI antibodies. Synthetic GPI glycoarrays have been
Table 1 Lectin speciﬁcities.
Sugar Lectina
Fucose AAL, LTL, UEA I
Galactose ACL, ECL, EEL, GSL I, GSL I–B4, Jacalin, MAL I, PNA, RCA I, RCA II, SBA
Glucose Con A, LCA, PSA
Mannose Con A, GNL, HHL, LCA, NPA, PSA
N-Acetylgalactosamine BPL, DBA, GSL I, MPL, PTL, RCA I, RCA II, SJA, SBA, VVA, WFA
N-Acetylglucosamine DSL, GSL II, LEL, STL, WGA
Sialic acid MAL II, SNA
Complex structures PHA-E, PHA-L
a AAL: Aleuria Aurantia Lectin; LTL: Lotus Tetragonolobus Lectin; UEA I: Ulex Europaeus Agglutinin I; ACL: Amaranthus Caudatus Lectin; ECL:
Erythrina Cristagalli Lectin; EEL: Erythrina Cristagalli Lectin; GSL I: Griﬀonia (Bandeiraea) Simplicifolia Lectin I; MAL I: Maackia Amurensis
Lectin I; PNA: Peanut Agglutinin; RCA I: Ricinus Communis Agglutinin I; RCA II: Ricinus Communis Agglutinin II; SBA: Soybean Agglutinin;
ConA: Concanavalin A; LCA: Lens Culinaris Agglutinin; PSA: Pisum Sativum Agglutinin; GNL: Galanthus Nivalis Lectin; HHL: Hippeastrum
Hybrid Lectin; NPL: Narcissus Pseudonarcissus Lectin; BPL: Bauhinia Purpurea Lectin; DBA: Dolichos Biorus Agglutinin; MPL: Maclura
Pomifera Lectin; PTL: Psophocarpus Tetragonolobus Lectin; SJA: Sophora Japonica Agglutinin; VVA: Vicia Villosa Lectin; WFA: Wisteria
Floribunda Lectin; DSL: Datura Stramonium Lectin; GSL II: Griﬀonia (Bandeiraea) Simplicifolia Lectin II; LEL: Lycopersicon Esculentum
(Tomato) Lectin; STL: Solanum Tuberosum (Potato) Lectin; WGA: Wheat Germ Agglutinin; MAL II: Maackia Amurensis Lectin II; SNA:
Sambucus Nigra Lectin; PHA-E: Phaseolus vulgaris Erythroagglutinin; PHA-L: Phaseolus vulgaris Leucoagglutinin. Reproduced with permission
from http://www.vectorlabs.com/catalog.aspx?catID¼31


























used to establish the binding specicity measurements for anti-
GPI antibodies, correlate antibody levels and protection from
severe malaria and aid eﬃcient carbohydrate-based antitoxin
vaccine design.47
3.4 Analysis of phosphorylated sugar structures
A special and important subset of glycan microarrays has been
developed for the analysis of phosphorylated sugar structures.
7 The specicity of cation-dependent and -independent mannose
6-phosphate receptors (CD-MPR and CI-MPR) for high
mannose-type N-glycans of dened structures containing zero,
one, or two Man-P-GlcNAc phosphodiester or Man-6-P phos-
phomonoester residues was determined by a phosphorylated
glycan microarray.52 The diﬃculty in dening the specic
interactions of P-type lectins with glycans containing Man-6-P
or Man-P-GlcNAc was due to the lack of dened glycan struc-
tures for direct binding or inhibition studies.34
Song et al.26 have exploited a bifunctional uorescent linker,
2-amino-N-(2-aminoethyl)-benzamide (AEAB), to generate
a library of uorescently labeled high mannose-type N-glycans,
prepared from bovine ribonuclease B and soybean agglutinin
(Fig. 3). The glycans were puried, characterized, and enzy-
matically modied by a recombinant GlcNAc-
phosphotransferase to contain Man-P-GlcNAc phospho-
diesters. The amine-activated glycans were printed and cova-
lently bound on N-hydroxysuccinimide-activated glass slides
followed by treatment with diﬀerent concentrations of CD-MPR
or CI-MPR.26,308 Using this novel uorescent derivatization
method, many commercially available free reducing glycans
could be derivatized.
3.5 Clinical applications
The clinical application of glycan microarrays has risen sharply
in recent years. A good example of this is the use of Keyhole
limpet hemocyanin (KLH), a large molecular weight glycopro-
tein of marine origin, which is extensively utilized for basic
research and clinical applications of glycan microarray tech-
niques. Due to its high immunogenicity and low toxicity, KLH
has become the standard carrier protein for making mono-
clonal and polyclonal antibodies against such small molecule
haptens as oligosaccharides.53 Several peptide-KLH conjugates
and carbohydrate-KLH conjugates have even progressed to
clinical trials as cancer vaccines.54,55
A carbohydrate microarray method has also been used to
prole the antibody responses in 14 individuals immunized
with KLH plus alum adjuvant.56 However, while the appropriate
immune response to carbohydrate antigens is a major compo-
nent of this method, it may vary signicantly from person to
person. Apparently, glycan microarrays have been useful for
evaluating such responses.57 Another interesting development
in the eld has been the high-throughput screening of inhibi-
tors to block carbohydrate-mediated molecular recognition in
specic biomedical applications, also utilizing carbohydrate
microarray methods.58
In the work of Lawrie et al.,59 a glycan microarray containing
37 covalently bound carbohydrates was used to identify sugar
structures that triggered a humoral immune response in clas-
sical Hodgkin’s lymphoma (cHL) patients. This carbohydrate
microarray enabled the investigation of glycan variations of
specic proteins in patient populations, also in response to
changing conditions.5
4 Conclusions
In recent years, glycoarrays have become standard tools for
screening a great number of sugar–biomolecule interactions
and for investigating the role of carbohydrates in biological
systems, especially in large scale diagnostic applications.
Glycan microarrays have been applied in the determination of
Fig. 3 The general strategy of natural glycan array development using complex glycoconjugates as starting materials. Reproduced with
permission from Ref. 30.


























the sugar-binding proles of proteins, nucleic acids, whole
cells, and pathogens, just to mention the most important ones,
and have provided valuable information for the design of
carbohydrate-based drugs. Glycan arrays also constitute an
attractive platform for the analysis of serum samples, opening
up the way for a wide variety of biomedical applications, such as
the identication of novel sugar based biomarkers to diagnose
early-stage diseases and the detection and diagnosis of patho-
genic infections.47
Natural glycans can be utilized as an almost unlimited
source of glycan structures.51 The recognition of complex
carbohydrates by glycan binding proteins is a good way of
interpreting the glycome and providing information on its
involvement in biological processes. However, modern glycomic
research shows that each cell and tissue of every organism
generates a wide variety of glycans and each cell type has
a distinctive repertoire of glycan structures. In addition,
hundreds of glycan binding proteins have been identied and
many more are predicted to be discovered.30
Currently, microarrays are primarily used as research tools,
however, they will quickly nd their place in large scale
biomedical applications. Sugar microarrays represent a prom-
ising platform to shed light on structure–function relationships
of sugar–sugar, sugar–protein, sugar–lipid, etc., interactions at
the global level. The incubation of glycoarrays with serum or
plasma samples opens up new avenues for novel medically
relevant applications, including the identication of carbohy-
drate cancer markers and specic identications of pathogen
infections. The identication of markers in early-stage cancers
could lead to improved therapies and survival rates of patients.
In recent years a number of glycan microarray platforms,
based on the specic (covalent or non-covalent) immobilization
of chemically conjugated glycans on a modied surface, have
been developed for high-throughput glycomic research.
Carbohydrate arrays vary in ligand presentation, glycan origin
(chemically synthesized or isolated from natural sources), assay
conditions, detection method, microsphere based suspension
array (SA) and immobilization on at surfaces (printed glycan
array, ELISA); all of which contribute to the aﬃnity and selec-
tivity of the binding.
With the aim of automating the synthesis of complex
carbohydrates, a number of sophisticated chemical methodol-
ogies have been developed for the rapid generation of glycan
libraries. The approach has been pioneered by Seeberger’s
group60 utilizing solid-phase synthesis to carry out the iterative
glycosylation and deprotection steps. They have capitalized on
this method, along with more traditional solution-phase
synthesis, to create libraries of heparin sulfate glycans and
high-mannose oligosaccharides.8,61,62 Another elegant tech-
nology is the Optimer-based one-pot, solution-phase oligosac-
charide synthesis method.63 In this system, a computer program
is used to select the appropriate glycosyl donor and acceptor
building blocks such that when added sequentially to a reaction
vessel the desired oligosaccharide is assembled.
Future perspectives
Miniaturized methodologies in microarray formats are partic-
ularly promising in the elds of biomedical research and clin-
ical diagnostics. While DNA microarray technology has the
advantage of utilizing the polymerase chain reaction (PCR)
based amplication and cloning strategies to produce high
quantities of nucleotides even if starting from just a few copies,
protein and carbohydrate microarrays currently lack such
amplication techniques facing a limited sample availability
issue. While protein microarrays usually utilize antibodies for
interrogation, carbohydrate microarrays can use either anti-
bodies or special carbohydrate-binding proteins (e.g., lectins) to
detect binding. Both approaches can be used in diagnostic and/
or prognostic applications or to characterize carbohydrate-cell
or carbohydrate-microbe recognition events.64
There are myriads of possibilities for the use of microarray
technologies in biomedical and diagnostic applications.21
During the last decade, glycan microarrays have moved from
a proof of principle concept to a powerful glycobiology research
toolset. Despite the documented utilization of glycan micro-
arrays, the progress to date represents only the beginning. One
of the challenges in the interpretation of glycan array data is to
determine the specic features of glycan structures that are
critical for binding. Microarrays have been useful tools for
determining the specicity of glycan binding proteins and
certain surface oligosaccharides that might be an important
element for cell–cell communication.
The identication of all the glycan structures associated with
particular cells is underway. Databases containing published
glycan sequences are already providing information on the scale
and diversity of the glycome. It has been estimated that 500–600
endogenous unique glycan structures are present in glycopro-
teins and glycolipids in mammalian systems. Expansion of the
glycan content of glycan microarrays to cover the majority of
known glycans will therefore be one of the most important
challenges for the next few years. Bacterial polysaccharides and
other pathogen and microorganism related glycans will
certainly be involved in future array designs as well.12
Abbreviations
AEAB 2-Amino-N-(2-aminoethyl)-benzamide
CD-MPR Cation-dependent mannose 6-phosphate receptor
CI-MPR Cation-independent mannose 6-phosphate receptor
ER Endoplasmic reticulum
GBP Glycan binding protein
GPI Glycosylphosphatidylinositol
MPR Mannose 6-phosphate receptor
MR Mannose receptor
PGA Printed glycan array
SA Suspension array
TGL Tagged glycan libraries
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